Euphemisms, Ambiguity and Interest Rates

“It is clear that the decline of a language must ultimately have political and economic causes . . . It becomes ugly and inaccurate because our thoughts are foolish, but the slovenliness of our language makes it easier for us to have foolish thoughts. The point is that the process is reversible… If one gets rid of these habits one can think more clearly, and to think clearly is a necessary first step”

– George Orwell


 

George Orwell was renowned for his disapproval of modern English language. He believed that the use of metaphors, abbreviations, crude words and euphemisms constructed limits to rational thought processes and creativity. In his dystopian novel 1984, which I’m sure I’ve referenced before, the totalitarian government develops a language called Newspeak which removes any undesirable concepts and is a tool to control self-expression and individuality. For example, instead of the words “good, better and bad” in Newspeak ybig-brother-poster-1984ou would use “good, doublegood, and ungood”. By reducing the amount of words in the English language the Party is able carry out both their political and economic agendas more freely.

The finance world is ripe with these linguistic techniques. While financiers aren’t necessarily vying for complete domination (directly), this simplicity evolved from the need for fast-paced communication in order for economies to be more efficient and productive.

However, I would make the argument that financial institutions incorporate this colloquial language constantly to bend market sentiment to their will. Whether positive or negative, investors get lost in the tundra of phrases and lingo, unable to capture the true meaning. Shrouded in ambiguity, these establishments are able to manipulate surrounding opinions.

To me one of the most obvious examples surrounds the “the Great Recession”. I included quotations because the economic crisis of 2008 was not a recession. In actuality one could argue that it was a depression. There are many definitions for what constitutes an economic depression. According to Wikipedia (Yes, this is my blog and I’m a college graduate so I can use Wikipedia if I want… sorry Professors) a depression can be a decline in real GDP exceeding 10%, a recession lasting more than 2 years, or four quarters of negative GDP.

GDP Growth Rate

Let’s take a look at the charts. Yeah, four quarters of negative growth from July 2008 to July 2009. Now why would anyone in the finance industry prefer to call the crash a recession compared to a depression? The bankers, hedge funds, the Federal Reserve, the US government – they all want to lessen the severity of “the Great Recession” so that they could restore investor and consumer confidence in themselves. Thus they steer clear of anything to do with depression.

One of the main reasons for the mortgage crisis of 2008 was subprime lending which is a great term for confusing the general public. Subprime lending really entailed lenders preying on low income individuals with poor credit. Providing these borrowers with easy credit with little regard for the consequences led to excess defaults and the collapse of multiple financial institutions such as Lehman Brothers. Read between the lines.

When it comes to monetary policy the Federal Reserve is great at using these limited communication techniques to mystify speculators. The best example is the concept of “quantitative easing”. QE is nothing more than a euphemism for creating money out of thin air. By inflating their balance sheet the Fed is able to successfully dilute the currency and artificially stimulate the economy. The term “quantitative easing” is a fantastic word for the Fed to demonstrate that they actually had an easy fix for the economy. This expression provides assurance that the government isn’t actually as incompetent as they seem. While Ben Bernanke takes a lot of credit for his ‘successful’ policy, the US economy is currently having trouble reaching a meager 2% growth rate.

 

May 18th FOMC Minutes

The Federal Reserve monetary policy continues to dominate the market headlines. Janet Yellen loves to talk about the possibility of raising rates but besides the hike in December 2015 they have been unable to do so. However, before every rate hike meeting there is plenty of speculation and market movement resulting from the ambiguous language used by Yellen and her posse.

During the May 18th FOMC meeting minutes the Federal Reserve sent investors a warning that a June rate hike was not completely off the table. Before the meeting there was little possibility of a rate hike but according to the Wall Street Journal, traders in the futures market put a 34% probability on a move by the June 14-15 meeting, up from just 4% a few days before.

There definitely have been some positive economic data releases in the past couple of weeks that provide some explanation to the changing expectations. U.S. retail and food services sales for April were $453.4 billion, an increase of 1.3 percent from March, the CPI rose by .4% in April signaling inflation might be starting to pick up, and the housing sector continued to show signs of improvement as the number of building permits rose.

This was countered by a weak labor report and economic output expanding at a disappointing 0.5% annual pace.

The main reason that the rate hike expectations increased? Because the Fed continued to incorporate optimistic rhetoric throughout the minutes. Atlanta Fed President Dennis Lockhart said he wouldn’t take a June increase off the table, and Dallas Fed President Robert Kaplan called for rate increases “in the not-too-distant future” and said he might advocate for a move in June or July.

In terms of the low growth Fed officials signaled they weren’t overly worried about the apparent slump, judging it was temporary and “could partly reflect measurement problems and, if so, would likely be following by stronger growth in subsequent quarters,” the minutes said.

Seriously how much more indecisive can the Fed be? Janet Yellen is like a mother telling her children that the cat “ran away” even through their father hit it with his car two hours earlier. This change in language was intended to convey the Committee’s sense that the risks associated with global developments had diminished somewhat. All the Fed is trying to do is make it look like they still have multiple options and flexibility in terms of monetary policy when in reality they have their backs against the wall. I would be shocked if they raise rates in June. As long as the delusion persists that they will raise rates the market will continue to rally after the Fed doesn’t actually raise the rates. It’s a self-perpetuating cycle that will continue to prop up the stock market as investors will continue to pour money into riskier assets in search of yield. Finally, if the Fed actually does raise rates these artificial stock valuations could enter correction territory… All because Yellen is very good at using simple words to convince people of something she most likely (hypocrite) won’t do.

 

http://www.wsj.com/articles/fed-minutes-officials-keep-open-possibility-of-june-rate-increase-1463594811

Click to access fomcminutes20160427.pdf

http://www.nber.org/releases/

Valeant: Don’t Invest… Sorry Bill

Valeant Pharmaceuticals (VRX) rose 10% in midday trading on Tuesday May 3rd. They have made some big moves in the past couple of months to avoid any more of a decline in shareholder value. The 10-K statement was finally submitted last Friday, which will help Valeant avoid technically defaulting on their roughly $30 billion in total debt. They have added activist investor Bill Ackman to the board — whose hedge fund, Pershing Square, owns a 9% stake. Joseph Papa the departing CEO of Irish rival Perrigo (PRGO), was appointed Valeant’s new CEO last month, to replace Michael Pearson.AckmanSadBeach

Shares of Valeant are down 63% on the year, as Congressional and SEC investigations continue into the drugmaker’s pricing and accounting practices, leading to the delayed filing of Valeant’s 10-K statement with the SEC. They are accused of price gouging or buying drug companies and raising the prices on their products, faulty accounting principles, and overly aggressive expansion techniques.

So with Valeant’s recent “rebound” are they a good investment to potentially buy at a discounted stock price? Despite their recovery they are not yet in the clear. Here’s why:

 

Aggressive Unsustainable Growth

Part of Valeant’s historic business strategy has included acquiring and integrating businesses, products, technologies or other asset to help drive future growth. Valeant often moves very rapidly to negotiate and consummate the transaction, once they identify the acquisition target. In Michael Pearson’s testimony to the Special Senate Committee he admits, “Over the past few years Valeant has grown quickly and substantially… We have also made mistakes. Valeant was too aggressive and in some cases we regret pursuing transactions when they were based on increasing price”.

Their whole strategy reflects optimizing shareholder returns without concern for actual internal company structure or organic growth.

With Valeant’s use of financial engineering, investors have learned once again the problem of “roll-up” companies where the growth is driven by accounting and valuation multiples rather than economies of scale. The virtuous circle of cheap financing for takeovers leading to higher valuations leading to cheap financing works only as long as they keep doing deals. Valeant’s market value is down $78 billion from its peak.

Their current indebtedness imposes a $250 million aggregate cap on acquisitions, restricts the incurrence of debt to finance such acquisitions and requires the net proceeds from certain asset sales be used to repay the term loans instead of being reinvested in the business. In 2016 and possibly beyond, a substantial portion of their cash flow from operations will be allocated to service debt, thus reducing the amount of cash flow available for other purposes, including acquisitions.

Thus Valeant can’t pursue their normal strategy of aggressive acquisitions for the next couple of years.

 

Asset Write Downs

Amortization and impairments of finite-lived intangible assets increased $868 million, or 56%, to $2.42 billion in 2015 primarily due to amortization of 2014 and 2015 acquisitions in 2015 and the write-off of intangible assets in the fourth quarter of 2015 of $79 million in connection with the termination of the arrangements with and relating to Philidor and an impairment charge in the third quarter of 2015 of $26 million related to Zelapar® resulting from declining sales trends.

Overall, there was an increase of $9 billion in Goodwill, with $8 billion of the $13 billion Salix fair value being Goodwill.

If a company management team is constantly writing down goodwill and other intangible assets, it is giving off a telltale signal that management has made poor decisions. Investors may want to rethink the investment.

 

Debt

Valeant’s corporate credit rating was downgraded from Ba3 to B2 and then to B1 by Moody’s. S&P downgraded their rating from BB- to B. Both Moody’s and Standard & Poor’s have indicated that our corporate credit rating remains under review for potential further downgrade.

Valeant’s current long-term debt is a whopping $30,265 billion.

Under the indentures governing our outstanding senior notes, if Valeant does not file required reports within specified time periods, they will be in default due to the breach of the reporting covenant in the indentures. This would permit a majority of the lenders to accelerate the loans. Valeant may not have the funds to satisfy these loans.

They could be forced into bankruptcy or liquidation and, as a result, investors could lose all or a portion of their investment in the securities.

 

Brand Recovery

Valeant relied on price hikes to sustain its acquisition binge to fund growth. Great examples include drugs Isuprel and Nitropress which they acquired in 2015 and quickly raised the prices by 525% and 212%, respectively. They must stabilize prices to drugs they already own and establish price limits to drugs that they acquire in the future. Only by easing these prices can they restore their brand with customers, regulators and shareholders.

Obviously this is going to cut heavily into Valeant’s bottom line. There will be significant asset write downs and impairments for drugs with reduced prices. Expect to see Valeant divest some of the drugs that are no longer profitable.

Valeant will also have to quickly repair the damages created by the accounting errors. Certain sales transactions for deliveries to Philidor in the second half of 2014 were not executed in the normal course of business under applicable accounting standards. They should have been recognized on a sell-through basis (i.e., record revenue when Philidor dispensed the products to patients) rather than incorrectly recognized on the sell-in basis (at point of the delivery). Valeant has already taken action terminating all arrangements with and relating to Philidor.

 

Conclusion

These proceedings, investigations and inquiries could have a material adverse effect on Valeant’s reputation, business, and financial condition potentially causing the market value of common shares and/or debt securities to decline. Valeant isn’t just a business that made a few mistakes and now they are ready to shoot back to $260 a share. Their business model is truly broken. They use debt to finance acquisitions and then cover those interest expenses with price hikes. When the regulators put an end to this, Valeant will have to rely on organic growth and internal R&D to continue to remain competitive. Without the proper cash flow to currently invest in core businesses or make acquisitions due to the debt payment schedule their business model will be strained in the next couple of years.

 

 

http://realmoney.thestreet.com/articles/05/03/2016/valeant-shares-spike-new-ceo-joseph-papa-takes-office?puc=yahoo&cm_ven=YAHOO

http://hsprod.investis.com/shared/v2/irwizard/sec_item_new.jsp?epic=valeant_pharmaceuticals&ipage=10899192&DSEQ=&SEQ=&SQDESC=